Chemotherapy-Induced Leukoencephalopathy: A Case Series

Abstract

Rationale: Leukoencephalopathy, a complication associated with chemotherapy has been reported after giving high doses of methotrexate and cytarabine with no specific risk factors to date. 

Objectives:

  1. To review the prevalence of chemotherapy-induced leukoencephalopathy in children with acute lymphoblastic leukemia (ALL).
  2. To present the clinical course, pathogenesis and neuro-imaging findings of chemotherapy-induced leukoencephalopathy in children with ALL.

Case: We reported three cases of adolescent ALL precursor B-cell patients who received high doses of methotrexate and presented with neurologic and MRI findings consistent with leukoencephalopathy. Our patients were only placed on supportive measures with adequate hydration, without providing any special intervention. Yet, all of them had complete neurological recovery. 

Discussion and Summary: Methotrexate is a cell cycle-specific agent that inhibits the enzyme dihydrofolate reductase, preventing the conversion of folic acid to tetrahydrofolic acid and inhibiting cell replication. It is one of the most commonly implicated drug causing leukoencephalopathy.[3] On MRI T2-weighted images, all of them had hyperintensities on the posterior frontal/parietal corona radiata and centrum semiovale consistent with leukoencephalopathy. Complete recovery happened spontaneously in all of the cases. There is no standard treatment for acute and subacute toxicities from methotrexate. 

Keywords: Leukoencephalopathy, Chemotherapeutic drugs, Neurotoxicity, Case series

  1. Salkade P, Lim T. Methotrexate-induced acute toxic leukoencephalopathy. J Can Res Ther [Internet]. 2012;8(2):292. Available from: http://dx.doi.org/10.4103/0973-1482.98993

  2. Pizzo PA, Poplack DG. Principles and practice of pediatric oncology. 7th ed. Philadelphia, PA: Lippincott Williams and Wilkins; 2016. Chapter 44, p 1113 .

  3. Cavaliere R, Schiff D. Neurologic toxicities of cancer therapies. Curr Neurol Neurosci Rep [Internet]. 2006 May;6(3):218–26. Available from: http://dx.doi.org/10.1007/s11910-006-0009-8 

  4. Filley CM, Kleinschmidt-DeMasters BK. Toxic Leukoencephalopathy. N Engl J Med [Internet]. 2001 Aug 9;345(6):425–32. Available from: http://dx.doi.org/10.1056/NEJM200108093450606 

  5. Ziereisen F, Dan B, Azzi N, Ferster A, Damry N, Christophe C. Reversible acute methotrexate leukoencephalopathy: atypical brain MR imaging features. Pediatr Radiol [Internet]. 2005 Dec 21;36(3):205–12. Available from: http://dx.doi.org/10.1007/s00247-005-0015-z 

  6. Baker WJ, Royer GL Jr, Weiss RB. Cytarabine and neurologic toxicity. JCO [Internet]. 1991 Apr;9(4):679–93. Available from: http://dx.doi.org/10.1200/JCO.1991.9.4.679

  7. Vagace JM, de la Maya MD, Caceres-Marzal C, Gonzalez de Murillo S, Gervasini G. Central nervous system chemotoxicity during treatment of pediatric acute lymphoblastic leukemia/lymphoma. Critical Reviews in Oncology/Hematology [Internet]. 2012 Nov;84(2):274–86. Available from: http://dx.doi.org/10.1016/j.critrevonc.2012.04.003 

  8. Peddi PF, Peddi S, Santos ES, Morgensztern D. Central nervous system toxicities of chemotherapeutic agents. Expert Review of Anticancer Therapy [Internet]. 2014 Apr 21;14(7):857–63. Available from: http://dx.doi.org/10.1586/14737140.2014.911089 

  9. El-Hakam LM, Ramocki MB, Riviello JJ, Illner A. Hyperperfusion on magnetic resonance imaging in acute chemotherapy-related leukoencephalopathy. J Child Neurol [Internet]. 2010 Apr 2;25(6):776–9. Available from: http://dx.doi.org/10.1177/0883073809346349 

  10. Sindhwani G. MRI in chemotherapy induced leukoencephalopathy: report of two cases and radiologist’s perspective. JCDR [Internet]. 2017; Available from: http://dx.doi.org/10.7860/JCDR/2017/29164.10248

  11. Osborn AG, Blaser SI, Salzman KL. Diagnostic Imaging: Brain. Canada: AMIRSYS; 2004. Chapter Volume 1 Section 10-46

  12. Tian H, Cronstein BN. Understanding the mechanisms of action of methotrexate: implications for the treatment of rheumatoid arthritis. Bull NYU Hosp Jt Dis. 2007;65(3):168–73.

  13. Whitehead, M. MD, POG 9903 Polymorphism in methylenetetrahydrofolate reductase (MTHFR) and methotrexate (MTX) neurotoxicity in childhood B-progenitor cell ALL, Dec 2000, p4.

  14. Cohen IJ. Neurotoxicity after high-dose methotrexate (MTX) is adequately explained by insufficient folinic acid rescue. Cancer Chemother Pharmacol [Internet]. 2017 Apr 28;79(6):1057–65. Available from: http://dx.doi.org/10.1007/s00280-017-3304-y 

  15. Smith GA, Damon LE, Rugo HS, Ries CA, Linker CA. High-dose cytarabine dose modification reduces the incidence of neurotoxicity in patients with renal insufficiency. JCO [Internet]. 1997 Feb;15(2):833–9. Available from: http://dx.doi.org/10.1200/JCO.1997.15.2.833

Articles related to the one you are viewing

There are currently no results to show, please try again later

CC BY: Open Access Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/